| Literature DB >> 24288948 |
Amir Ghorbanihaghjo1, Javid Safa, Samira Alizadeh, Hassan Argani, Nadereh Rashtchizadeh, Mohammad Vahid Taghinia, Mehran Mesgari Abbasi.
Abstract
The study examined the influence of fish oil (FO) supplementation on serum 8-hydroxy-2'-deoxyguanosine (8-OHdG) levels as indicated by DNA damage markers and total antioxidant capacity (TAC) among male cigarette smokers. This double-blind, placebo-controlled randomized study was conducted among healthy cigarette smokers (n=40) who were part of a larger prospective cohort study. Twenty smokers were randomly selected to receive FO for 3 months (1 g/day), and another 20 smokers received a placebo for 3 months; 8-OHdG and TAC levels were measured in blood samples before and after the intervention. Serum 8-OHdG significantly decreased (p=0.001) and TAC increased (p<0.001) after 3 months of treatment with FO. Between baseline and endline, the difference in 8-OHdG significantly correlated with the difference in TAC among smokers who received FO (r=-0.540, p=0.014). The study provides evidence that FO supplementation can modify decreased antioxidants and increased oxidative DNA damage in cigarette smokers.Entities:
Mesh:
Substances:
Year: 2013 PMID: 24288948 PMCID: PMC3805884 DOI: 10.3329/jhpn.v31i3.16826
Source DB: PubMed Journal: J Health Popul Nutr ISSN: 1606-0997 Impact factor: 2.000
Age and baseline characteristics of cigarette smokers vs never-smokers
| Variable | Cigarette smokers (n=40) | Never-smokers (n=40) | p valuea |
|---|---|---|---|
| Age (years) | 40.20±7.86 | 38.70±8.24 | 0.408 |
| Serum 8-OHdGb (ng/mL) | 61.82±37.77 | 34.92±23.83 | 0.001 |
| Serum TACc (mmol/L) | 1.39±0.15 | 1.49±0.18 | 0.017 |
aCigarette smokers vs never-smokers at baseline;
b8-hydroxy-2’-deoxyguanosine;
cTotal antioxidant capacity
Figure 1.8-hydroxy-2'-deoxyguanosine (8-OHdG) and TAC levels in blood serum (r=-0.882, p<0.001) among cigarette smokers at baseline
Baseline and post-treatment measures of serum 8-OHdG and TAC among cigarette smokers in fish oil intervention and placebo groups
| Variable | Fish oil group (n=20) | Placebo group (n=40) | p value |
|---|---|---|---|
| Age (years) | 40.60±8.83 | 39.80±6.97 | 0.752 |
| Serum 8-OHdG | |||
| Baseline | 63.47±40.58 | 60.17±35.72 | 0.776 |
| 3 months | 53.22±37.40 | 64.28±40.20 | |
| (p=0.001) | (p=0.104) | ||
| Serum TAC | |||
| Baseline | 1.39±0.13 | 1.40±0.17 | 0.718 |
| 3 months | 1.47±0.15 | 1.39±0.17 | |
| (p<0.001)c | (p=0.844)d | ||
Data are mean±SD;
aFish oil group vs placebo group at baseline;
b8-hydroxy-2’-deoxyguanosine;
cBefore treatment vs after treatment with fish oil;
dBefore treatment vs after treatment with placebo;
eTotal antioxidant capacity
Figure 2.Changes in 8-hydroxy-2'-deoxyguanosine (Δ8-OHdG) and TAC (ΔTAC) serum levels between baseline and 3 months among smokers receiving FO (r=-0.540, p=0.014)